Literature DB >> 12171903

Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.

Michael H Wu1, Bingfang Yan, Rod Humerickhouse, M Eileen Dolan.   

Abstract

Carboxylesterases play a critical role in the bioactivation of the anticancer prodrug irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin; CPT-11] into its active metabolite SN-38 (ethyl-10-hydroxy-camptothecin). We reported recently that human carboxylesterase-2 (hCE-2) is a higher-affinity, higher-velocity enzyme for irinotecan hydrolysis when compared with hCE-1. To further investigate the role of these isoforms, we cloned both cDNAs into the human colorectal adenocarcinoma cell line HT29. Extracts of HT29 cells transfected with hCE-2 exhibited significantly higher irinotecan hydrolysis (5.2 pmol/mg protein/hr) than hCE-1 (1.0 pmol/mg protein/hr). HT29 cells over-expressing hCE-2 were more sensitive to the toxic effects of irinotecan than cells expressing hCE-1 (EC50 = 0.3 micro M and 6.8 micro M, respectively). Our data further support the notion that hCE-2 plays a substantial role in irinotecan activation in human tissue at relevant pharmacologic concentrations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171903

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Ontogenic expression of human carboxylesterase-2 and cytochrome P450 3A4 in liver and duodenum: postnatal surge and organ-dependent regulation.

Authors:  Yi-Tzai Chen; Lynnie Trzoss; Dongfang Yang; Bingfang Yan
Journal:  Toxicology       Date:  2015-02-24       Impact factor: 4.221

Review 2.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

3.  A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.

Authors:  Gwi-Moon Seo; Raja Shekar Rachakatla; Sivasai Balivada; Marla Pyle; Tej B Shrestha; Matthew T Basel; Carl Myers; Hongwang Wang; Masaaki Tamura; Stefan H Bossmann; Deryl L Troyer
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

4.  A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model.

Authors:  Matthew T Basel; Sivasai Balivada; Tej B Shrestha; Gwi-Moon Seo; Marla M Pyle; Masaaki Tamura; Stefan H Bossmann; Deryl L Troyer
Journal:  Small       Date:  2012-01-11       Impact factor: 13.281

5.  Suppression of carboxylesterases by imatinib mediated by the down-regulation of pregnane X receptor.

Authors:  Wenjing Luo; Yu Xin; Xia Zhao; Feng Zhang; Changqing Liu; Hongwei Fan; Tao Xi; Jing Xiong
Journal:  Br J Pharmacol       Date:  2017-03-03       Impact factor: 8.739

6.  The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.

Authors:  Yue Shen; William Eades; William Liu; Bingfang Yan
Journal:  Drug Metab Dispos       Date:  2022-07-05       Impact factor: 3.579

7.  Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.

Authors:  Da Xiao; Deshi Shi; Dongfang Yang; Benjamin Barthel; Tad H Koch; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2012-12-07       Impact factor: 5.858

8.  Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.

Authors:  Dongfang Yang; Robin E Pearce; Xiliang Wang; Roger Gaedigk; Yu-Jui Yvonne Wan; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2008-10-15       Impact factor: 5.858

9.  Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.

Authors:  Da Xiao; Dongfang Yang; Liangran Guo; Wei Lu; Margaret Charpentier; Bingfang Yan
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

10.  The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.

Authors:  Yasuhiro Tsume; Gordon L Amidon
Journal:  Molecules       Date:  2012-03-26       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.